
Browsing restrictions can be lifted for a fee.
G&E Herbal Biotechnology Co., Ltd., a biopharmaceutical company, focuses on the development and commercialization of novel botanical extraction technology and products. It offers botanical anti-aging cosmetic products, such as facial foam cleanser and cleansing essence, botanical extract toner, lightening lotion, essential oil, and moisturizing serum and cream; SR-100 botanical essence and bromelain illuminating cleansing mousse; and hepato protective agent capsules. The company also provides botanical healthcare products comprising ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules; and adult products. In addition, it is developing Solarise injection for the treatment of gynecologic, head, and neck cancer; Apocin capsule to treat non-small cell lung cancer; and SR-T100 Gel for the treatment of common and genital warts. Further, the company manufactures technology development for various dietary supplements, as well as provides technical advisory services to other biotechnology organizations. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.
4911
德英
-0.84%
(-0.01)
The most recent financial report for 德英 (4911) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4911's short-term business performance and financial health. For the latest updates on 4911's earnings releases, visit this page regularly.
According to historical valuation range analysis, 德英 (4911)'s current price-to-earnings (P/E) ratio is 20.19, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 德英 (4911) reported an Operating Profit of 40.19M with an Operating Margin of 50.38% this period, representing a growth of 19.98% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 德英 (4911) announced revenue of 79.78M, with a Year-Over-Year growth rate of 28.15%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 德英 (4911) held Total Cash and Cash Equivalents of 59.57M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 德英 (4911) achieved the “three margins increasing” benchmark, with a gross margin of 84.72%%, operating margin of 50.38%%, and net margin of 45.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4911's profit trajectory and future growth potential.
According to the past four quarterly reports, 德英 (4911)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.57. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
德英 (4911)'s Free Cash Flow (FCF) for the period is 247K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 103.9% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.